CEA ELISA Kit (Carcinoembryonic Antigen)

INTENDED USE

Human CEA ELISA kit can be used for analysing in vitro quantitative amounts of carcinoembryonic antigen (CEA) in human serum. This assay has a minimum sensitivity limit of < 0.596 ng/ml.

BACKGROUND

Carcinoembryonic antigen (CEA) is a glycoprotein which is 200 kD and is mainly involved in cell adhesion. It is normally only produced during fetal development within the gastrointestinal tissue and the production stop immediately before birth. It was first discovered in human colon cancer tissue extracts and it has been later identified that the level of this antigen also correlates with the tumor stage.

There have been a number of tumors which are now associated with elevated levels of CEA which include stomach, lung, colon, breast gullet and pancreatic carcinomas. Its measurement is predominately used as a tumor marker in order to monitor colorectal cancer treatment, staging, localise cancer spread and to identify recurrences.

CONTENT

All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.

• Microtiterwells: Coated with anti-CEA antibody (monoclonal).
• Zero Standard.
• Standards (1-5): Concentrations 5, 10, 25, 50, 100 ng/mL.
• Control Low & High (Lyophilized).
• Enzyme Conjugate: Monoclonal anti-CEA antibody conjugated to horseradish peroxidase.
• Substrate Solution: Tetramethylbenzidine (TMB).
• Stop Solution: Contains 0.5 M H2SO4.
• Wash Solution (40x Concentrated).

SENSITIVITY

The minimum detection sensitivity level of carcinoembryonic antigen (CEA) using current CEA ELISA kit was < 0.596 ng/ml. The dynamic range for this assay is 3.0 – 100.0 ng/ml.

ASSAY CHARACTERISTICS

– Assay Dynamic Range: 0.596 – 100 ng/mL
– Specificity of Antibodies (Cross Reactivity): Cross-reactivities are not known.
– Analytical Sensitivity: < 0.596 ng/mL
– Intra-Assay Variations: 3.2 – 4.9%
– Inter-Assay Variations: 5.6 – 6.3%
– Recovery: 85.8 – 107.0%
– Linearity: 89.9 – 114.6%
– High-Dose-Hook Effect: No hook effect was observed up to 8,000 ng/mL of CEA.
– Interfering Substances: Haemolytic, icteric and lipemic sera should be avoided.
– Drug Interference: Smokers have been reported to exhibit increased levels of CEA.

REFERENCES

1. CEA – a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. (2013) 56 (7): 859-68. Wallin U., et al.
2. Carcinoembryonic-antigen (CEA) as tumor marker in lung cancer. Lung Cancer. (2012) 76 (2): 138-43. Review. Grunnet M. and Sorensen J.B.
3. Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: is follow-up by CEA justified? Hepatogastroenterology. (2005) 52 (62): 444-9. Yamamoto S., et al.
4. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. (1999) 9 (2): 67-81. Review. Hammarström S.

ADDITIONAL INFORMATION

• Full Name: CEA ELISA Kit (Carcinoembryonic Antigen)
• Reactivity: Human
• Sample Type: Serum
• Sensitivity: 0.596 ng/ml

OTHER RELATED ELISA KITS

• Chromogranin A ELISA Kit
• Cancer Antigen 125 ELISA Kit
• Neuron Specific Enolase (NSE) ELISA Kit